Rockwell Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2012; unaudited. Rockwell manufactures and sells hemodialysis concentrates and related products, primarily in the U.S., and is developing renal drug therapies, led by SFP (soluble ferric pyrophosphate).
Financial performance
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Sales | $12.1 million | $11.8 million | $24.2 million | $25.1 million |
| Gross profit / margin | $1.7 million / 14.2% | $1.1 million / 9.1% | $3.3 million / 13.9% | $2.7 million / 10.8% |
| Research and product development | $10.9 million | $3.3 million | $20.3 million | $5.7 million |
| Net loss | $11.9 million | $4.5 million | $22.5 million | $7.5 million |
| Loss per share, basic and diluted | $0.58 | $0.26 | $1.12 | $0.43 |
- Q2 sales increased 2.7% year over year; first-half sales declined about 3.7%. The first-half decrease mainly reflected a $1.4 million reduction in sales to one international distributor.
- Gross margin improved in both periods, which management attributed to product and customer mix, increased dry-acid concentrate sales, and lower operating costs. Dry products reduce customers’ costs and shipping expense but can reduce sales revenue.
- Operating loss was $12.0 million in Q2 and $22.7 million for the first half, compared with $4.6 million and $7.6 million, respectively, in 2011. The much higher clinical-development spending, primarily for SFP Phase III trials, was the principal pressure on results.
- First-half operating cash use was $14.8 million, versus $5.0 million in 2011. Investing activities used $2.2 million; financing provided $17.8 million, principally from share and warrant issuance. Cash increased $0.8 million to $6.5 million.
Financial position and liquidity
- At June 30, cash and cash equivalents were $6.5 million and available-for-sale investments were $13.9 million, totaling $20.4 million. Current assets were $29.4 million and current liabilities $17.4 million, leaving working capital of approximately $12.0 million.
- Total liabilities were approximately $17.4 million, almost all current; capitalized lease obligations totaled about $4,000. Shareholders’ equity was $16.7 million.
- In February, the company raised $17.5 million gross, or approximately $16.2 million net, in a common-stock offering; warrant exercises generated a further approximately $1.6 million during the first half.
Outlook, risks, and notable items
- Management expected substantial research and development spending over the next two years and operating losses until SFP is approved and marketed. It stated available and prospective resources were sufficient for anticipated R&D and ordinary operating needs in 2012.
- Management expected positive 2012 operating cash flow excluding R&D, assuming stable revenue, fuel, and key raw-material markets. It noted potential additional funding needs if development costs or testing exceed expectations; approximately $8.0 million of warrants expiring in 2012 could provide proceeds if exercised.
- The company was conducting human clinical trials for SFP and pursuing FDA approval. It expected to begin marketing Calcitriol in early 2013, subject to approval of a manufacturing-location change; the final $550,000 acquisition-related cash payment was made in Q3 2012.
- Key risks include dependence on a small number of large dialysis customers, competition from a larger competitor, regulatory and clinical-trial uncertainty, possible need for additional financing, and exposure to healthcare funding and regulation.
- Short-term bond-fund investments had $175,950 of unrealized losses and had been in a loss position for more than 12 months. Management did not consider them other-than-temporarily impaired; it said a hypothetical 100-basis-point rate change would not materially affect portfolio value.
- Management reported disclosure controls effective at the reasonable-assurance level and said a previously identified weakness in recording clinical-trial R&D expenses had been remediated by March 31, 2012. The filing also notes significant noncash equity compensation, contributing to higher SG&A.
Important facts for investors to verify
- Progress, results, timing, regulatory pathway, and remaining cost of SFP Phase III trials and FDA approval.
- Cash runway and actual operating cash flow, including whether the assumptions behind management’s 2012 outlook hold and whether warrants are exercised or new financing is needed.
- Revenue concentration and trends in major customer accounts, international distributors, and product mix.
- Whether gross-margin gains persist as customers shift from liquid to dry concentrates, and whether the company can control development and operating costs.
- Follow-up evidence supporting remediation of the R&D accrual control weakness and the status of Calcitriol’s manufacturing approval.